// App-Quantinova.ai

P67 : LONG‐TERM MANAGEMENT OF MODERATE‐TO‐SEVERE ATOPIC DERMATITIS WITH DUPILUMAB AND CONCOMITANT TOPICAL CORTICOSTEROIDS: A 1‐YEAR RANDOMIZED, PLACEBO‐CONTROLLED PHASE 3 TRIAL (CHRONOS)

Researchers

Presenter

  • A Blauvelt

Principal Investigators

  • M Gooderham

  • P Foley

  • Griffiths CEM

  • JC Cather

  • M de Bruin-Weller

  • X Zhu

  • B Akinlade

  • Graham NMH

  • G Pirozzi

  • B Shumel

Medical Centers

  • Oregon Medical Research, Portland, OR, USA

  • SKiN Centre for Dermatology, Peterborough, ON, Canada

  • University of Melbourne, Parkville, Australia

  • Dermatology Centre, Salford Royal Hospital, University of Manchester, Manchester, United Kingdom

  • Mindful Dermatology and Modern Research Associates, Dallas, USA

  • University Medical Center Utrecht, Utrecht, Netherlands

  • Sanofi, Bridgewater, NJ

Locations

  • United States

  • Canada

  • Australia

  • United Kingdom

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

Disease

  • Atopic Dermatitis

Biomarkers

  • N/A

Drug/Treatment

  • Dupilumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • NCT02260986

Sponsors

  • Sanofi Genzyme And Regeneron Pharmaceuticals

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved